Oncology and Hematology

196-210 of 290

• 

  RestartResume

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  MinuteCE®

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  • 

    

    Aparna R. Parikh, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

  MinuteCE®

  Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

  • 

    

    Aparna R. Parikh, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Emerging Directions in Biomarker-Directed Therapy for GI Malignancies

  MinuteCE®

  Emerging Directions in Biomarker-Directed Therapy for GI Malignancies

  • 

    

    Alan Venook, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence   

  MinuteCE®

  Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence   

  • 

    

    Alan Venook, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

  MinuteCE®

  Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

  • 

    

    Sara Lonardi, MD

    Peer

  • 

    

    Aparna R. Parikh, MD

    Peer

  • 

    

    Alan Venook, MD

    Peer

  1.25 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 credits 10 episodes
• advertisement

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Gynecologic Cancer

  • 

    

    Susana Campos, MD, MPH

    Peer

  • 

    

    Nicoletta Colombo, MD

    Peer

  • 

    

    Ritu Salani, MD, MBA

    Peer

  1.00 credits 10 episodes

• 

  RestartResume

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  MinuteCE®

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  MinuteCE®

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  MinuteCE®

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits
• advertisement

• 

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  MinuteCE®

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  MinuteCE®

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging targeted therapy combination strategies in genitourinary malignancies

  • 

    

    Ignacio Duran, MD

    Peer

  1.25 program credits

• Prev
• 1
• 2
• …
• 12
• 13
• 14
• 15
• 16
• …
• 19
• 20
• Next